Research Summary: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are B-cell malignancies that frequently affect older adults and often require prolonged use of Bruton tyrosine kinase inhibitor (BTKi) therapy in the relapsed or refractory (R/R) setting. Ibrutinib and acalabrutinib are both recommended BTKis...
Read MoreAcalabrutinib Monotherapy vs Combination Therapy in Treatment-Naïve CLL Study Snapshot Study: Retrospective real-world study Population: Patients with treatment-naïve chronic lymphocytic leukemia (CLL) Sample size: 81 patients (monotherapy: n=21; combination: n=60) Treatment: Acalabrutinib monotherapy vs acalabrutinib + obinutuzumab Focus: Efficacy and safety comparison as first-line treatment...
Read MoreReprinted with permission. Clin Exp Med. 2025;26(1):80.* by Aviwe Ntsethe and Bongani Brian Nkambule Dr. Ntsethe is with Department of Human Physiology, Nelson Mandela University, Gqeberha, South Africa. Dr. Nkambule is with School of Laboratory Medicine and Medical Sciences (SLMMS), College of Health Sciences, University...
Read MoreHeterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL) Tian S, Wang H, Parikh SA, et al. Leuk Res. 2026;160:108133. Summary. In this study, researchers compared the genomic profiles of 5 patients with chronic lymphocytic leukemia (CLL) and 7 patients with Richter...
Read MoreLearn how acalabrutinib compares to other CLL treatments, with insights on cardiac safety, atrial fibrillation risk, and what recent trials reveal about treatment options.
Read MoreExplore the latest CLL research, including genetic insights, immune responses, and emerging diagnostic tools shaping prognosis and personalized treatment strategies.
Read MoreExplore key CLL updates from EHA 2025, including treatment safety, genetic risk factors, and new tools improving diagnosis and personalized care.
Read More©2026 Oncology Matrix. All Rights Reserved.
